newsfilter
← Latest News
Business Wire·

Gemini Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

- Fast Track Designation for GEM103 in dry AMD granted January 2021 - GEM103 Phase 2a study in geographic atrophy data on track for June 2021 - GEM103 Phase 2a as a possible add-on therapy for patients with wet AMD at risk for macular atrophy com